Mutational signatures and kataegis in pediatric B-cell precursor acute lymphoblastic leukemia [0.03%]
儿童前体B细胞急性淋巴细胞白血病中的突变特征和Kataegis现象
Rebeqa Gunnarsson,Minjun Yang,Andrea Biloglav et al.
Rebeqa Gunnarsson et al.
Metabolism in hematology: Technological advances open new perspectives on disease biology and treatment [0.03%]
血液学中的代谢：技术进步为疾病生物学和治疗提供了新的视角
Eileen Haring,Joerg M Buescher,Petya Apostolova
Eileen Haring
The term metabolism refers to the multi-faceted biochemical reactions within a cell or an organism that occur to maintain energy homeostasis, cell growth, and oxidative balance. Cells possess a high metabolic plasticity, allowing them to ad...
Quality of vitamin K antagonist treatment during the last year of life [0.03%]
生命最后一年维生素K抗凝药物使用质量的研究
Chantal Visser,Eva K Kempers,Jamilla Goedgebuur et al.
Chantal Visser et al.
Limited data exist on the quality of anticoagulation in patients approaching the end of life. This study evaluated vitamin K antagonist (VKA) anticoagulation control during the last year of life, using nationwide data from Statistics Nether...
Correction to Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study [0.03%]
关于I型戈谢病患者中隐匿性或复发多发性骨髓瘤患病率：CHAGAL前瞻性观察研究结果的更正通知
[This corrects the article DOI: 10.1002/hem3.70079.]. © 2025 The Author(s). HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematolo...
Published Erratum
HemaSphere. 2025 May 14;9(5):e70142. DOI:10.1002/hem3.70142 2025
Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD-1 blockade [0.03%]
PD-1阻断时代复发/难治性经典型霍奇金淋巴瘤治疗的优化策略
Thomas M Kuczmarski,Ryan C Lynch
Thomas M Kuczmarski
Editorial
HemaSphere. 2025 May 12;9(5):e70110. DOI:10.1002/hem3.70110 2025
Sirpa Leppä,Leo Meriranta,Maare Arffman et al.
Sirpa Leppä et al.
Survival rates for patients with high-risk large B-cell lymphoma (LBCL), particularly those with biological risk factors, remain inadequate. We conducted a biomarker-driven phase II trial involving 123 high-risk patients aged 18-64 with LBC...
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up [0.03%]
外周T细胞淋巴瘤和自然杀伤细胞淋巴瘤：诊断、治疗和随访的ESMO-EHA临床实践指南
Francesco d&#x;Amore,Massimo Federico,Laurence de Leval et al.
Francesco d&#x;Amore et al.
Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV) [0.03%]
早期真性红细胞增多症患者无事件生存期与罗匹干扰素阿尔法-2b或羟基脲/最佳支持治疗的分子学反应相关(PROUD-PV/CONTINUATION-PV)
Jean-Jacques Kiladjian,Christoph Klade,Pencho Georgiev et al.
Jean-Jacques Kiladjian et al.
Correction to Summary of Joint European Hematology Association (EHA) and EuroBloodNet recommendations on diagnosis and treatment of methemoglobinemia [0.03%]
对欧洲血液学协会(EHA)和EuroBloodNet甲基硫菌灵诊断和治疗建议的总结的更正
[This corrects the article DOI: 10.1097/HS9.0000000000000660.]. © 2025 The Author(s). HemaSphere published by John Wiley & Sons Ltd on behalf of Europea...
Published Erratum
HemaSphere. 2025 May 3;9(5):e70144. DOI:10.1002/hem3.70144 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma [0.03%]
纳武单抗联合异环磷酰胺、卡铂和依托泊苷可作为高危复发/难治性霍奇金淋巴瘤患者的高效一线挽救方案
Matthew Mei,Joycelynne Palmer,Hun Ju Lee et al.
Matthew Mei et al.
Nivolumab is an anti-PD-1 antibody that is effective in patients with relapsed/refractory (RR) classic Hodgkin lymphoma (cHL). We previously showed PET-adapted sequential nivolumab ± ifosfamide, carboplatin, and etoposide (ICE) chemotherap...